Capmatinib disables your Nrf2 anti-oxidant response in severe myeloid leukaemia tissue increasing reactive oxygen species-mediated killing. Website: http://en.wikipedia.org/wiki/Proto-oncogene_tyrosine-protein_kinase_Src